BTK — Drug Target
All drugs that target BTK — marketed and clinical-stage. Includes 2 drug classes acting on this target.
Drug classes
BTK inhibitor · Bruton's tyrosine kinase (BTK) inhibitor
Marketed (1)
- (G) BQ-L14 · National Taiwan University Hospital · BTK inhibitor · Oncology
BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK).
Phase 3 pipeline (4)
- FFI-1010 · Fuji Yakuhin Co., Ltd. · BTK inhibitor · Oncology
FFI-1010 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. - LBL-007 · BeiGene · Bruton's tyrosine kinase (BTK) inhibitor · Oncology
LBL-007 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies. - Orelabrutinib and R-CHOP · Beijing InnoCare Pharma Tech Co., Ltd. · BTK inhibitor · Oncology
Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the activity of BTK, a protein involved in the activation of B cells. - V0034CR01B · Pierre Fabre Medicament · BTK inhibitor · Oncology
This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
Phase 2 pipeline (9)
- Acalabrutinib combination with Rituximab · AstraZeneca · BTK inhibitor · Oncology
BTK inhibitor - CE-224,535 · Pfizer · BTK inhibitor · Oncology
CE-224,535 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. - GSK1292263 · GlaxoSmithKline · BTK inhibitor · Oncology
GSK1292263 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. - ABBV-668 · AbbVie · BTK inhibitor · Oncology
ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK). - LOXO-305 · Eli Lilly and Company · BTK inhibitor · Oncology
Selective Bruton's tyrosine kinase (BTK) inhibitor - Acalabrutinib monotherapy · AstraZeneca · Bruton's tyrosine kinase (BTK) inhibitor · Oncology
Acalabrutinib inhibits Bruton's tyrosine kinase (BTK), which blocks B-cell activation and proliferation. - ACP-196 · Acerta Pharma BV · BTK inhibitor · Oncology
BTK inhibitor - GZ402665 · Genzyme, a Sanofi Company · BTK inhibitor · Oncology
GZ402665 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. - AUR101 · Aurigene Discovery Technologies Limited · BTK inhibitor · Oncology
AUR101 is a small molecule inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.
Phase 1 pipeline (6)
- Acalabrutinib in combination with BR · Acerta Pharma BV · BTK inhibitor · Oncology
BTK inhibitor - ABBV-453 · AbbVie · BTK inhibitor · Oncology
BTK inhibitor - Acalabrutinib Treatment C · AstraZeneca · BTK inhibitor · Oncology
BTK inhibitor - Acalabrutinib in combination with VR · Acerta Pharma BV · BTK inhibitor · Oncology
BTK inhibitor - Acalabrutinib Treatment D · AstraZeneca · BTK inhibitor · Oncology
BTK inhibitor - Acalabrutinib Treatment A · AstraZeneca · BTK inhibitor · Oncology
BTK inhibitor